Dr Aymen Idris, MSc, PhD
Senior lecturer of musculoskeletal pharmacology
Targeting and disrupting bone – immune – cancer cell communications for the prevention and treatment of both skeletal and non-skeletal complications associated with bone disease.
Tel: +44 (0) 114 215 9068
The primary interest of Dr Idris’ group is in the area of pharmacology of inflammation induced bone remodelling associated with a variety of bone diseases. The specific aims of Dr Idris’ research are to (a) uncover novel druggable pro-inflammatory signal transduction pathways essential for the regulation of bone – immune – malignant cell interactions, and (b) guided by this knowledge, develop new therapeutic agents for the prevention and treatment of both skeletal and non-skeletal complications associated with bone disease.
One of Dr Idris’ particular areas of interests is the effects of cannabis-like substances on bone and cancer pharmacology. In this area, Dr Idris carried out significant research on the skeletal effects of endocannabinoids and their receptors on bone biology with publications in Nature Medicine, Endocrinology and Cell Metabolism. Dr Idris also conducted research into the role of the NFκB signalling pathway in bone disease resulting in a number of publications in Endocrinology, FASEB J and JBMR, and a series of patents of a novel family of NFkB inhibitors, which exhibit anti-resorptive, anti-inflammatory and anti-tumour properties.